<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02191527</url>
  </required_header>
  <id_info>
    <org_study_id>EGPAF-004</org_study_id>
    <nct_id>NCT02191527</nct_id>
  </id_info>
  <brief_title>Evaluating the Effectiveness of Point-of-care Diagnostic Technologies in MCH Services in Mozambique</brief_title>
  <official_title>Evaluating the Effectiveness of Point-of-care Diagnostic Technologies in MCH Services and Their Impact on Mother and Child Health Outcomes in Cabo Delgado Province, Mozambique</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elizabeth Glaser Pediatric AIDS Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Mozambique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Elizabeth Glaser Pediatric AIDS Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The general goal of the proposed study is to evaluate the cost-effectiveness of POC
      technologies for diagnosis of syphilis, quantitative analysis for hemoglobin and CD4 counting
      performed within MCH services to improve maternal and infant health.

      A prospective, quasi-experimental study will be done in Cabo Delgado province, where health
      facilities will be randomized in an intervention or comparison arm. Outcomes on maternal and
      infant health will be measured.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Before and after intervention study design</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of HIV positive pregnant women initiating antiretroviral therapy among eligible women.</measure>
    <time_frame>Within 1 month</time_frame>
    <description>Number of HIV positive pregnant women initiating antiretroviral therapy divided by the number of eligible HIV positive pregnant women</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of women at first ANC visit tested and treated for syphilis</measure>
    <time_frame>Within 1 month</time_frame>
    <description>Number of women at first ANC tested and treated for syphilis divided by the number of women attending first ANC visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of pregnant women tested and treated for anemia</measure>
    <time_frame>Within 1 month</time_frame>
    <description>Number of pregnant women test and treated for anemia divided by the number of pregnant women</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of HIV infections in infants averted</measure>
    <time_frame>1-3 months of age</time_frame>
    <description>Number of HIV-positive pregnant women who accessed antiretrovial therapy in a timely manner</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1673</enrollment>
  <condition>HIV</condition>
  <condition>Syphilis</condition>
  <condition>Anemia During Pregnancy</condition>
  <arm_group>
    <arm_group_label>Point of Care Testing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The point-of-care devices will be located in the MCH services, where a trained lay counselor will do the tests.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laboratory Testing - Standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Samples sent to the laboratory for analysis, (standard of care)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PIMA® for quantitative analysis of CD4-count</intervention_name>
    <arm_group_label>Point of Care Testing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hemocue® (HemoCue AB, Angelhom, Sweden) for quantitative analysis of hemoglobin</intervention_name>
    <arm_group_label>Point of Care Testing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SD Bioline® (Standard Diagnostics Inc., South-Korea) for qualitative analysis of syphilis</intervention_name>
    <arm_group_label>Point of Care Testing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  First antenatal care visit

          -  Able to provide informed consent and signed consent form

          -  Minimum 18 years of age

          -  Diagnosed HIV positive at antenatal care visit

          -  Living in the catchment area of the health facility

        Exclusion Criteria:

          -  Age &lt;18 years

          -  No consent form signed

          -  Being on ART at time of first antenatal care visit
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caroline DeSchacht, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Elizabeth Glaser Pediatric AIDS Foundation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ilesh V Jani, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Saúde, Mozambique</affiliation>
  </overall_official>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 15, 2013</study_first_submitted>
  <study_first_submitted_qc>July 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2014</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PMTCT</keyword>
  <keyword>HIV</keyword>
  <keyword>Syphilis</keyword>
  <keyword>Anemia during pregnancy</keyword>
  <keyword>Point of care diagnostics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syphilis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

